Anecortave Acetate Risk-Reduction Trial (AART)

Efficacy and Safety of Posterior Juxtascleral Administrations of Anecortave Acetate for Depot Suspension (15 mg or 30 mg) Versus Sham Administration in Singaporean Patients at Risk for Progressing to Exudative Age-Related Macular Degeneration (AMD)

The purpose of this study was to demonstrate that Anecortave Acetate for Depot Suspension (15 mg or 30 mg) is safe and effective in arresting the progression of non-exudative (dry) age-related macular degeneration in patients who are at risk for progressing to exudative (wet) age-related macular degeneration.

Inclusion Criteria:

• Dry AMD in study eye, Wet AMD in non-study eye;
• Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

• Under 50;
• Other protocol-defined exclusion criteria may apply.